You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 587 Tumor-activated Fc-engineered anti-CTLA-4 monoclonal antibody, XTX101, demonstrates tumor-selective PD and efficacy in preclinical models

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Immune-stimulants and immune modulators
587 Tumor-activated Fc-engineered anti-CTLA-4 monoclonal antibody, XTX101, demonstrates tumor-selective PD and efficacy in preclinical models

 

Online download statistics by month:

Online download statistics by month: November 2020 to September 2024

AbstractFullPdf
Nov 2020143017
Dec 20203808
Jan 20215808
Feb 20214205
Mar 202148011
Apr 20214209
May 202112015
Jun 20213021
Jul 2021108
Aug 20210012
Sep 20210019
Oct 202172024
Nov 202186019
Dec 20214003
Jan 20224209
Feb 20222804
Mar 202284014
Apr 202274010
May 20226005
Jun 20224404
Jul 202286011
Aug 202278011
Sep 20222805
Oct 20224403
Nov 20225209
Dec 20222600
Jan 20233201
Feb 20233600
Mar 20237805
Apr 20232003
May 20232001
Jun 20233001
Jul 20232405
Aug 20232603
Sep 20233604
Oct 20234602
Nov 20235805
Dec 20234600
Jan 20242600
Feb 20242404
Mar 20243604
Apr 20241804
May 20241802
Jun 20243802
Jul 20247800
Aug 20241803
Sep 20241801
Total19570314